Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis

Diego Centonze, Francesco Mori, Giacomo Koch, Fabio Buttari, Claudia Codecà, Silvia Rossi, Maria Teresa Cencioni, Monica Bari, Stefania Fiore, Giorgio Bernardi, Luca Battistini, Mauro MacCarrone

Research output: Contribution to journalArticle

Abstract

The endocannabinoid system (ECS) is involved in the pathophysiology of multiple sclerosis (MS), and relief from pain and spasticity has been reported in MS patients self-medicating with marijuana. A cannabis-based medication containing Δ9-tetrahydrocannabinol and cannabidiol (Sativex®) has been approved in some countries for the treatment of MS-associated pain. The effects of this pharmaceutical preparation on other clinically relevant aspects of MS pathophysiology, however, are still unclear. In 20 MS patients, we measured the effects of Sativex® on clinically measured spasticity and on neurophysiological and laboratory parameters that correlate with spasticity severity or with the modulation of the ECS. Sativex® failed to affect spasticity and stretch reflex excitability. This compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both CB1 and CB2 cannabinoid receptors in various subpopulations of peripheral lymphocytes.

Original languageEnglish
Pages (from-to)531-534
Number of pages4
JournalNeurological Sciences
Volume30
Issue number6
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Cannabis
Multiple Sclerosis
Endocannabinoids
Cannabidiol
Cannabinoid Receptor CB2
Therapeutics
Cannabinoid Receptor CB1
Pain
Stretch Reflex
Dronabinol
Lymphocyte Subsets
Pharmaceutical Preparations
tetrahydrocannabinol-cannabidiol combination

Keywords

  • Endocannabinoid system
  • H-reflex
  • Inflammation
  • Pain
  • Sativex
  • Spasticity

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. / Centonze, Diego; Mori, Francesco; Koch, Giacomo; Buttari, Fabio; Codecà, Claudia; Rossi, Silvia; Cencioni, Maria Teresa; Bari, Monica; Fiore, Stefania; Bernardi, Giorgio; Battistini, Luca; MacCarrone, Mauro.

In: Neurological Sciences, Vol. 30, No. 6, 12.2009, p. 531-534.

Research output: Contribution to journalArticle

Centonze, Diego ; Mori, Francesco ; Koch, Giacomo ; Buttari, Fabio ; Codecà, Claudia ; Rossi, Silvia ; Cencioni, Maria Teresa ; Bari, Monica ; Fiore, Stefania ; Bernardi, Giorgio ; Battistini, Luca ; MacCarrone, Mauro. / Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. In: Neurological Sciences. 2009 ; Vol. 30, No. 6. pp. 531-534.
@article{96c10e6a7bd94b2f9a10ab5942513e80,
title = "Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis",
abstract = "The endocannabinoid system (ECS) is involved in the pathophysiology of multiple sclerosis (MS), and relief from pain and spasticity has been reported in MS patients self-medicating with marijuana. A cannabis-based medication containing Δ9-tetrahydrocannabinol and cannabidiol (Sativex{\circledR}) has been approved in some countries for the treatment of MS-associated pain. The effects of this pharmaceutical preparation on other clinically relevant aspects of MS pathophysiology, however, are still unclear. In 20 MS patients, we measured the effects of Sativex{\circledR} on clinically measured spasticity and on neurophysiological and laboratory parameters that correlate with spasticity severity or with the modulation of the ECS. Sativex{\circledR} failed to affect spasticity and stretch reflex excitability. This compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both CB1 and CB2 cannabinoid receptors in various subpopulations of peripheral lymphocytes.",
keywords = "Endocannabinoid system, H-reflex, Inflammation, Pain, Sativex, Spasticity",
author = "Diego Centonze and Francesco Mori and Giacomo Koch and Fabio Buttari and Claudia Codec{\`a} and Silvia Rossi and Cencioni, {Maria Teresa} and Monica Bari and Stefania Fiore and Giorgio Bernardi and Luca Battistini and Mauro MacCarrone",
year = "2009",
month = "12",
doi = "10.1007/s10072-009-0136-5",
language = "English",
volume = "30",
pages = "531--534",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "6",

}

TY - JOUR

T1 - Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis

AU - Centonze, Diego

AU - Mori, Francesco

AU - Koch, Giacomo

AU - Buttari, Fabio

AU - Codecà, Claudia

AU - Rossi, Silvia

AU - Cencioni, Maria Teresa

AU - Bari, Monica

AU - Fiore, Stefania

AU - Bernardi, Giorgio

AU - Battistini, Luca

AU - MacCarrone, Mauro

PY - 2009/12

Y1 - 2009/12

N2 - The endocannabinoid system (ECS) is involved in the pathophysiology of multiple sclerosis (MS), and relief from pain and spasticity has been reported in MS patients self-medicating with marijuana. A cannabis-based medication containing Δ9-tetrahydrocannabinol and cannabidiol (Sativex®) has been approved in some countries for the treatment of MS-associated pain. The effects of this pharmaceutical preparation on other clinically relevant aspects of MS pathophysiology, however, are still unclear. In 20 MS patients, we measured the effects of Sativex® on clinically measured spasticity and on neurophysiological and laboratory parameters that correlate with spasticity severity or with the modulation of the ECS. Sativex® failed to affect spasticity and stretch reflex excitability. This compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both CB1 and CB2 cannabinoid receptors in various subpopulations of peripheral lymphocytes.

AB - The endocannabinoid system (ECS) is involved in the pathophysiology of multiple sclerosis (MS), and relief from pain and spasticity has been reported in MS patients self-medicating with marijuana. A cannabis-based medication containing Δ9-tetrahydrocannabinol and cannabidiol (Sativex®) has been approved in some countries for the treatment of MS-associated pain. The effects of this pharmaceutical preparation on other clinically relevant aspects of MS pathophysiology, however, are still unclear. In 20 MS patients, we measured the effects of Sativex® on clinically measured spasticity and on neurophysiological and laboratory parameters that correlate with spasticity severity or with the modulation of the ECS. Sativex® failed to affect spasticity and stretch reflex excitability. This compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both CB1 and CB2 cannabinoid receptors in various subpopulations of peripheral lymphocytes.

KW - Endocannabinoid system

KW - H-reflex

KW - Inflammation

KW - Pain

KW - Sativex

KW - Spasticity

UR - http://www.scopus.com/inward/record.url?scp=70449533773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449533773&partnerID=8YFLogxK

U2 - 10.1007/s10072-009-0136-5

DO - 10.1007/s10072-009-0136-5

M3 - Article

C2 - 19768368

AN - SCOPUS:70449533773

VL - 30

SP - 531

EP - 534

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 6

ER -